Hemolytic Anemia

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia 12 29 6 15 38 63 17
Anemia, Hemolytic 44 40 72
Anemia Hemolytic 12 55


External Ids:

Disease Ontology 12 DOID:583
MeSH 44 D000743
NCIt 50 C34376
SNOMED-CT 68 61261009
ICD10 33 D55-D59
UMLS 72 C0002878

Summaries for Hemolytic Anemia

PubMed Health : 63 About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over. Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body. Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die. White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding. When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs. Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to congenital nonspherocytic hemolytic anemia and pyruvate kinase deficiency of red cells, and has symptoms including icterus An important gene associated with Hemolytic Anemia is SPTB (Spectrin Beta, Erythrocytic), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Ribavirin and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and bone, and related phenotypes are no effect and Increased simian virus 40 (SV40) infection

Wikipedia : 75 Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs),... more...

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies Rare Hemolytic Anemia

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1015)
# Related Disease Score Top Affiliating Genes
1 congenital nonspherocytic hemolytic anemia 34.6 PKLR NT5C3A GPI G6PD
2 pyruvate kinase deficiency of red cells 34.5 PKLR G6PD
3 congenital hemolytic anemia 34.0 SPTB SPTA1 PKLR HBB GPI G6PD
4 pyropoikilocytosis, hereditary 33.6 SPTB SPTA1
5 glucosephosphate dehydrogenase deficiency 33.5 HBB G6PD
6 glutathione synthetase deficiency 33.4 GSS G6PD
7 hereditary spherocytosis 33.1 SPTB SPTA1 SLC4A1 PKLR HBB G6PD
8 spherocytosis, type 3 33.0 SPTA1 HBB
9 hereditary elliptocytosis 32.8 SPTB SPTA1 SLC4A1 ANK1
10 glucosephosphate isomerase deficiency 31.7 GPI G6PD
11 neonatal jaundice 31.5 SPTA1 PKLR G6PD
12 beta-thalassemia 31.4 SPTB HBB G6PD
13 blood group incompatibility 30.7 SLC4A1 G6PD
14 kernicterus 30.7 SLC4A1 G6PD
15 malaria 30.4 SLC4A1 PKLR HBB G6PD ADAMTS13
16 hemolytic anemia, nonspherocytic, due to hexokinase deficiency 12.8
17 uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to 12.8
18 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 12.8
19 adenylate kinase deficiency, hemolytic anemia due to 12.8
20 glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to 12.7
21 warm antibody hemolytic anemia 12.7
22 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.7
23 renal tubular acidosis, distal, with hemolytic anemia 12.7
24 drug-induced autoimmune hemolytic anemia 12.6
25 hemolytic anemia, congenital, x-linked 12.6
26 anemia, autoimmune hemolytic 12.6
27 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.6
28 systemic lupus erythematosus with hemolytic anemia 1 12.5
29 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 12.5
30 adenosine deaminase, elevated, hemolytic anemia due to 12.4
31 hemolytic anemia with thermal sensitivity of red cells 12.4
32 autoimmune hemolytic anemia, warm type 12.4
33 mixed-type autoimmune hemolytic anemia 12.4
34 autoimmune hemolytic anemia, cold type 12.4
35 thrombotic thrombocytopenic purpura, congenital 12.4
36 rare hemolytic anemia 12.4
37 pulmonary arterial hypertension associated with chronic hemolytic anemia 12.3
38 glut1 deficiency syndrome 2 12.3
39 hemolytic anemia due to an erythrocyte nucleotide metabolism disorder 12.3
40 constitutional hemolytic anemia due to acanthocytosis 12.3
41 triosephosphate isomerase deficiency 12.3
42 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 12.2
43 rare acquired hemolytic anemia 12.2
44 rare constitutional hemolytic anemia 12.2
45 obsolete: hemolytic anemia due to glyceraldehyde-3-phosphate dehydrogenase deficiency 12.2
46 neonatal autoimmune hemolytic anemia 12.2
47 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.2
48 hemolytic anemia due to glutathione reductase deficiency 12.2
49 hemolytic anemia due to erythrocyte adenosine deaminase overproduction 12.2
50 hemolytic anemia due to a disorder of glycolytic enzymes 12.2

Graphical network of the top 20 diseases related to Hemolytic Anemia:

Diseases related to Hemolytic Anemia

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:


GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADAMTS13 AK1 ALDOA ANK1 CD59 EPB42
2 Increased simian virus 40 (SV40) infection GR00356-A-2 9.13 HK1 PGK1 PKLR

MGI Mouse Phenotypes related to Hemolytic Anemia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ADAMTS13 ANK1 CD59 EPB42 G6PD GPI
2 homeostasis/metabolism MP:0005376 9.8 ADAMTS13 AK1 ANK1 CD59 EPB42 G6PD
3 mortality/aging MP:0010768 9.4 ADAMTS13 ANK1 CD59 G6PD GCLC GPI

Drugs & Therapeutics for Hemolytic Anemia

PubMed Health treatment related to Hemolytic Anemia: 63

Treatments for hemolytic anemia include blood transfusions, medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery, blood and marrow stem cell transplants, and lifestyle changes. People who have mild hemolytic anemia may not need treatment, as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ribavirin Approved Phase 4 36791-04-5 37542
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 68911 119380
Nitric Oxide Approved Phase 4 10102-43-9 145068
Cefpirome Approved Phase 4 84957-29-9 5479539
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Prilocaine Approved Phase 4 721-50-6 4906
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Azathioprine Approved Phase 4 446-86-6 2265
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
Metformin Approved Phase 4 657-24-9 4091 14219
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
Desogestrel Approved Phase 4 54024-22-5 40973
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
25 Protective Agents Phase 4
26 Antioxidants Phase 4
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
28 Antibodies Phase 4
29 Immunoglobulins Phase 4
30 Antirheumatic Agents Phase 4
31 HIV Protease Inhibitors Phase 4
protease inhibitors Phase 4
33 Anti-HIV Agents Phase 4
34 Anti-Retroviral Agents Phase 4
35 Topoisomerase Inhibitors Phase 4
36 Immunoglobulins, Intravenous Phase 4
37 Interferon-alpha Phase 4
38 interferons Phase 4
39 Artemether, Lumefantrine Drug Combination Phase 4
40 Interferon alpha-2 Phase 4
41 gamma-Globulins Phase 4
42 Rho(D) Immune Globulin Phase 4
43 Contraceptives, Oral, Combined Phase 4
44 Norgestimate, ethinyl estradiol drug combination Phase 4
45 Cephalosporins Phase 4
46 Estradiol 3-benzoate Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Natriuretic Agents Phase 4
49 diuretics Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes. Completed NCT02090036 Phase 4 Primaquine (For artemether-lumefantrine+primaquine arm);Placebo (For artemether-lumefantrine arm)
3 Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
4 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4 Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
5 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study Completed NCT00491179 Phase 4 Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
6 A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C Completed NCT00172809 Phase 4 Peginterferon alfa-2a;Interferon alfa-2a
7 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
8 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
9 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
10 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
11 A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients Completed NCT00494741 Phase 4 mycophenolate mofetil;azathioprine
12 Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT02874066 Phase 4 PTV/r/OBV/DSV
13 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Recruiting NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
14 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Recruiting NCT02984475 Phase 4 Metformin
15 Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia Recruiting NCT03392298 Phase 4 Colla corii asini
16 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
17 Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
18 Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Active, not recruiting NCT03420300 Phase 4 EBR/GZR
19 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Not yet recruiting NCT03918265 Phase 4 Tacrolimus
20 Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
21 Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3 Alemtuzumab, Rituximab
22 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
23 Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C Completed NCT00001729 Phase 3 Ribavirin
24 Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies? Completed NCT00295516 Phase 3
25 Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO Completed NCT00645606 Phase 3
26 An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection Completed NCT00248339 Phase 3 Peginterferon-alpha-2b (PEG-Intron);Ribavirin;Epoetin-alpha (Procrit)
27 Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo Completed NCT02205541 Phase 3 Eculizumab;Placebo
28 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
29 An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies Recruiting NCT03853798 Phase 3 AG-348
30 An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency Recruiting NCT03559699 Phase 3 AG-348
31 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Recruiting NCT03347422 Phase 3 Sutimlimab;Placebo
32 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency Recruiting NCT03548220 Phase 3 AG-348;Placebo
33 A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Active, not recruiting NCT03347396 Phase 3 Sutimlimab
34 Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART) Active, not recruiting NCT00920621 Phase 3
35 High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4 Terminated NCT00662220 Phase 3 ribavirin;ribavirin
36 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
37 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
38 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
39 Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD) Unknown status NCT01202812 Phase 2
40 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
41 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
42 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
43 " Anemil Trial ": Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment Completed NCT02389231 Phase 1, Phase 2 Interleukine-2
44 CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
45 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab Completed NCT01303952 Phase 2 Eculizumab
46 The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy Completed NCT02689986 Phase 2 Bendamustine, Rituximab
47 A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions Completed NCT00110617 Phase 2 Deferasirox (ICL670);Deferoxamine (DFO)
48 Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease Completed NCT01696474 Phase 2 Bortezomib
49 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine. Completed NCT00373594 Phase 2 Rituximab;Fludarabine
50 A Phase II Study of Hematopoietic Stem Cell Therapy for Young Adults With Severe Sickle Cell Disease Completed NCT01565616 Phase 2 Conditioning Regimen with Bone Marrow Transplant

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :

alpha-Tocopherol Acetate
Cortisone acetate
d-alpha-Tocopheryl Acetate
dl-alpha tocopheryl acetate
Tocopherol Acetate
Vitamin E

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

# Genetic test Affiliating Genes
1 Hemolytic Anemia 29

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

Testes, Liver, Bone, Bone Marrow, Heart, Kidney, Spleen

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 12797)
# Title Authors PMID Year
Hemoglobin Sendagi (beta 42 Phe----Val): a new unstable hemoglobin variant having an amino acid substitution at CD1 of the beta-chain. 38 71
3781864 1986
Hemoglobin Louisville (beta-42 (CD1) phe-leu): an unstable variant causing mild hemolytic anemia. 38 71
5096522 1971
Hb south Milwaukee [beta 105 (G7) Leu----Phe]: a newly-identified hemoglobin variant with high oxygen affinity. 71
2363414 1990
A new Spanish family with Hb Louisville. 71
2705488 1989
Haemoglobin Buccureşti 42(CD1) Phe-Leu, a cause of unstable haemoglobin haemolytic anaemia. 71
5133275 1971
Gastrointestinal and hepatic complications of sickle cell disease. 9 38
20215064 2010
Glucose-6-phosphate dehydrogenase and red cell pyruvate kinase deficiency in neonatal jaundice cases in egypt. 9 38
20426517 2010
Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole. 9 38
20065266 2010
Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. 9 38
20007901 2009
Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. 9 38
19755962 2009
Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension. 9 38
19237250 2009
Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial. 9 38
19085014 2009
Sickle cell anemia in northern Israel: screening and prevention. 9 38
19603597 2009
A hemolysis trigger in glucose-6-phosphate dehydrogenase enzyme deficiency. Vicia sativa (Vetch). 9 38
19198723 2009
A case of cold agglutinin disease in the course of treatment for polymyalgia rheumatica. 9 38
19340395 2009
Brucellosis triggering hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. 9 38
19494543 2009
Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. 9 38
18983524 2008
A novel G6PD mutation leading to chronic hemolytic anemia. 9 38
18677765 2008
Glucose-6-phosphate dehydrogenase deficiency associated stuttering priapism: report of a case. 9 38
18823322 2008
Degradation of functional triose phosphate isomerase protein underlies sugarkill pathology. 9 38
18458110 2008
Hematological abnormalities in patients with distal renal tubular acidosis and hemoglobinopathies. 9 38
18266205 2008
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. 9 38
18371543 2008
Crystal structure of a core domain of stomatin from Pyrococcus horikoshii Illustrates a novel trimeric and coiled-coil fold. 9 38
18182167 2008
Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. 9 38
17716993 2007
Chronic non-spherocytic hemolytic anemia associated with severe neurological disease due to gamma-glutamylcysteine synthetase deficiency in a patient of Moroccan origin. 9 38
18024385 2007
Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. 9 38
17661373 2007
Point mutations involved in red cell stomatocytosis convert the electroneutral anion exchanger 1 to a nonselective cation conductance. 9 38
17554061 2007
Seven different glucose-6-phosphate dehydrogenase variants including a new variant distributed in Lam Dong Province in southern Vietnam. 9 38
17726510 2007
In vitro and in vivo expression of human erythrocyte pyruvate kinase in erythroid cells: a gene therapy approach. 9 38
17547515 2007
Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency. 9 38
17550844 2007
Cardiac hypertrophy in anion exchanger 1-null mutant mice with severe hemolytic anemia. 9 38
17056673 2007
Inborn errors in the metabolism of glutathione. 9 38
17397529 2007
Thrombotic microangiopathy in a sirolimus-treated renal transplant patient receiving gemcitabine for lung cancer. 9 38
17338432 2007
Improved quantitative method for G6PD deficiency detection. 9 38
17385678 2007
Glucose-6-phosphate dehydrogenase--from oxidative stress to cellular functions and degenerative diseases. 9 38
17623517 2007
Red cell glucose phosphate isomerase (GPI): a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia. 9 38
17041899 2006
Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. 9 38
16857429 2006
Two new mutations of the P5'N-1 gene found in Italian patients with hereditary hemolytic anemia: the molecular basis of the red cell enzyme disorder. 9 38
16956825 2006
Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. 9 38
16760505 2006
Reactivity of blood samples spotted onto filter papers in the WST-8 method for screening of G6PD deficiency. 9 38
16680190 2006
G6PD deficiency with hemolytic anemia due to a rare gene deletion--a report of the first case in Malaysia. 9 38
16753852 2006
Rh proteins: key structural and functional components of the red cell membrane. 9 38
15961204 2006
Hereditary erythrocyte pyrimidine 5'-nucleotidase deficiency: a biochemical, genetic and clinical overview. 9 38
16522554 2006
New insights into paroxysmal nocturnal hemoglobinuria. 9 38
17124035 2006
Hemolysis and methemoglobinemia secondary to rasburicase administration. 9 38
16204390 2005
Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. 9 38
16212642 2005
An adult with acute poststreptococcal glomerulonephritis complicated by hemolytic uremic syndrome and nephrotic syndrome. 9 38
16183409 2005
Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. 9 38
15870173 2005
Two new glucose-6-phosphate dehydrogenase mutations causing chronic hemolysis. 9 38
16079115 2005
Cardiac surgery for a patient with familial lecithin: cholesterol acyltransferase deficiency. 9 38
15997755 2005

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

6 (show top 50) (show all 70)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SPTB NM_001024858.3(SPTB): c.5794_5798+6delCCCAGGTGAGG deletion Pathogenic rs1555367318 14:65237597-65237607 14:64770879-64770889
2 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 11:5247995-5247995 11:5226765-5226765
3 HBB NM_000518.5(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 11:5247995-5247995 11:5226765-5226765
4 SLC4A1 NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45562031 17:42338993-42338993 17:44261625-44261625
5 SLC4A1 NM_000342.4(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 17:42325994-42325994 17:44248626-44248626
6 SLC4A1 NM_000342.4(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 17:42326150-42326150 17:44248782-44248782
7 SLC4A1 NM_000342.4(SLC4A1): c.*1606_*1608dup duplication Uncertain significance rs57466226 17:42326218-42326220 17:44248850-44248852
8 SLC4A1 NM_000342.4(SLC4A1): c.*1608del deletion Uncertain significance rs57466226 17:42326218-42326218 17:44248850-44248850
9 SLC4A1 NM_000342.4(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 17:42326628-42326628 17:44249260-44249260
10 SLC4A1 NM_000342.4(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 17:42330587-42330587 17:44253219-44253219
11 SLC4A1 NM_000342.4(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 17:42333204-42333204 17:44255836-44255836
12 SLC4A1 NM_000342.4(SLC4A1): c.636A> G (p.Ser212=) single nucleotide variant Uncertain significance rs886053000 17:42336923-42336923 17:44259555-44259555
13 SLC4A1 NM_000342.4(SLC4A1): c.286C> T (p.Arg96Cys) single nucleotide variant Uncertain significance rs538778224 17:42338066-42338066 17:44260698-44260698
14 SLC4A1 NM_000342.4(SLC4A1): c.*1273G> T single nucleotide variant Uncertain significance rs769140134 17:42326553-42326553 17:44249185-44249185
15 SLC4A1 NM_000342.4(SLC4A1): c.*947C> G single nucleotide variant Uncertain significance rs368389948 17:42326879-42326879 17:44249511-44249511
16 SLC4A1 NM_000342.4(SLC4A1): c.*872G> C single nucleotide variant Uncertain significance rs886052994 17:42326954-42326954 17:44249586-44249586
17 SLC4A1 NM_000342.4(SLC4A1): c.2630T> C (p.Ile877Thr) single nucleotide variant Uncertain significance rs765911147 17:42328552-42328552 17:44251184-44251184
18 SLC4A1 NM_000342.4(SLC4A1): c.2208C> T (p.Asn736=) single nucleotide variant Uncertain significance rs766674440 17:42330589-42330589 17:44253221-44253221
19 SLC4A1 NM_000342.4(SLC4A1): c.1431+15G> T single nucleotide variant Uncertain significance rs886052999 17:42335012-42335012 17:44257644-44257644
20 SLC4A1 NM_000342.4(SLC4A1): c.884G> A (p.Arg295His) single nucleotide variant Uncertain significance rs140424071 17:42335984-42335984 17:44258616-44258616
21 SLC4A1 NM_000342.4(SLC4A1): c.876+14G> A single nucleotide variant Uncertain significance rs571092411 17:42336517-42336517 17:44259149-44259149
22 SLC4A1 NM_000342.4(SLC4A1): c.697C> G (p.Arg233Gly) single nucleotide variant Uncertain significance rs779054292 17:42336710-42336710 17:44259342-44259342
23 SLC4A1 NM_000342.4(SLC4A1): c.202G> A (p.Glu68Lys) single nucleotide variant Uncertain significance rs13306787 17:42338150-42338150 17:44260782-44260782
24 SLC4A1 NM_000342.4(SLC4A1): c.2701C> T (p.Arg901Trp) single nucleotide variant Uncertain significance rs201265160 17:42327861-42327861 17:44250493-44250493
25 G6PD NM_000402.4(G6PD): c.1186A> G (p.Lys396Glu) single nucleotide variant Uncertain significance rs1057518975 X:153760973-153760973 X:154532758-154532758
26 SLC4A1 NM_000342.4(SLC4A1): c.-135G> A single nucleotide variant Uncertain significance rs183529485 17:42345488-42345488 17:44268120-44268120
27 SLC4A1 NM_000342.4(SLC4A1): c.-65C> A single nucleotide variant Uncertain significance rs886053001 17:42340299-42340299 17:44262931-44262931
28 SLC4A1 NM_000342.4(SLC4A1): c.-30C> T single nucleotide variant Uncertain significance rs148028272 17:42340264-42340264 17:44262896-44262896
29 SLC4A1 NM_000342.4(SLC4A1): c.457C> A (p.Leu153Met) single nucleotide variant Uncertain significance rs145041032 17:42337800-42337800 17:44260432-44260432
30 SLC4A1 NM_000342.4(SLC4A1): c.*1316C> T single nucleotide variant Uncertain significance rs886052991 17:42326510-42326510 17:44249142-44249142
31 SLC4A1 NM_000342.4(SLC4A1): c.*1596A> C single nucleotide variant Uncertain significance rs886052990 17:42326230-42326230 17:44248862-44248862
32 SLC4A1 NM_000342.4(SLC4A1): c.-136C> T single nucleotide variant Uncertain significance rs566359654 17:42345489-42345489 17:44268121-44268121
33 SLC4A1 NM_000342.4(SLC4A1): c.-60G> A single nucleotide variant Uncertain significance rs75489266 17:42340294-42340294 17:44262926-44262926
34 SLC4A1 NM_000342.4(SLC4A1): c.173A> G (p.Tyr58Cys) single nucleotide variant Uncertain significance rs368863744 17:42338179-42338179 17:44260811-44260811
35 SLC4A1 NM_000342.4(SLC4A1): c.1225G> A (p.Val409Ile) single nucleotide variant Uncertain significance rs201821517 17:42335411-42335411 17:44258043-44258043
36 SLC4A1 NM_000342.4(SLC4A1): c.1431+13T> G single nucleotide variant Uncertain significance rs747632229 17:42335014-42335014 17:44257646-44257646
37 SLC4A1 NM_000342.4(SLC4A1): c.*1608dup duplication Uncertain significance rs57466226 17:42326218-42326218 17:44248850-44248850
38 SLC4A1 NM_000342.4(SLC4A1): c.2243G> A (p.Gly748Glu) single nucleotide variant Uncertain significance rs886052996 17:42330554-42330554 17:44253186-44253186
39 SLC4A1 NM_000342.4(SLC4A1): c.2482-9C> T single nucleotide variant Uncertain significance rs886052995 17:42328709-42328709 17:44251341-44251341
40 SLC4A1 NM_000342.4(SLC4A1): c.*351G> T single nucleotide variant Uncertain significance rs138242019 17:42327475-42327475 17:44250107-44250107
41 SLC4A1 NM_000342.4(SLC4A1): c.*977G> A single nucleotide variant Uncertain significance rs886052993 17:42326849-42326849 17:44249481-44249481
42 SLC4A1 NM_000342.4(SLC4A1): c.*1237C> T single nucleotide variant Uncertain significance rs774513767 17:42326589-42326589 17:44249221-44249221
43 SLC4A1 NM_000342.4(SLC4A1): c.*1273del deletion Uncertain significance rs768606768 17:42326553-42326553 17:44249185-44249185
44 SLC4A1 NM_000342.4(SLC4A1): c.*1103del deletion Likely benign rs111655803 17:42326723-42326723 17:44249355-44249355
45 SLC4A1 NM_000342.4(SLC4A1): c.*408C> T single nucleotide variant Likely benign rs45555735 17:42327418-42327418 17:44250050-44250050
46 SLC4A1 NM_000342.4(SLC4A1): c.*1227A> C single nucleotide variant Likely benign rs141425539 17:42326599-42326599 17:44249231-44249231
47 SLC4A1 NM_000342.4(SLC4A1): c.*135G> A single nucleotide variant Likely benign rs566741511 17:42327691-42327691 17:44250323-44250323
48 SLC4A1 NM_000342.4(SLC4A1): c.*270G> A single nucleotide variant Likely benign rs5027 17:42327556-42327556 17:44250188-44250188
49 SLC4A1 NM_000342.4(SLC4A1): c.*794del deletion Likely benign rs45515496 17:42327032-42327032 17:44249664-44249664
50 SLC4A1 NM_000342.4(SLC4A1): c.*349G> A single nucleotide variant Likely benign rs1465204 17:42327477-42327477 17:44250109-44250109

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 12.33 HK1 HBB G6PD ALDOA
Show member pathways
Show member pathways
7 11.74 PGK1 HK1 ALDOA
Show member pathways
9 11.48 PGK1 HK1 ALDOA
Show member pathways
Show member pathways
12 11.02 SPTB SPTA1 ANK1
13 10.62 PKLR PGK1
Show member pathways
10.29 HK1 GPI G6PD
15 10.13 PGK1 HK1 GPI G6PD

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 SLC4A1 PKLR PGK1 HBB GSS GPI
2 ficolin-1-rich granule lumen GO:1904813 9.61 HBB GPI ALDOA
3 cytoplasmic side of plasma membrane GO:0009898 9.5 SPTA1 G6PD ANK1
4 spectrin GO:0008091 9.4 SPTB SPTA1
5 intrinsic component of the cytoplasmic side of the plasma membrane GO:0031235 9.37 SPTB SPTA1
6 cortical cytoskeleton GO:0030863 9.13 SPTA1 SLC4A1 EPB42
7 spectrin-associated cytoskeleton GO:0014731 8.8 SPTB SPTA1 ANK1
8 cytosol GO:0005829 10 SPTB SPTA1 PKLR PGK1 NT5C3A HK1

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.76 PKLR HK1 GPI G6PD
2 regulation of cell shape GO:0008360 9.73 SPTA1 EPB42 ALDOA
3 ER to Golgi vesicle-mediated transport GO:0006888 9.73 SPTB SPTA1 CD59 ANK1
4 actin filament capping GO:0051693 9.54 SPTB SPTA1
5 gluconeogenesis GO:0006094 9.54 PGK1 GPI ALDOA
6 regulation of blood vessel size GO:0050880 9.52 HBB GCLC
7 glutathione biosynthetic process GO:0006750 9.51 GSS GCLC
8 bicarbonate transport GO:0015701 9.5 SLC4A1 RHAG HBB
9 erythrocyte maturation GO:0043249 9.49 G6PD EPB42
10 response to xenobiotic stimulus GO:0009410 9.48 GSS GCLC
11 response to cadmium ion GO:0046686 9.43 GSS GPI GCLC
12 cellular ion homeostasis GO:0006873 9.4 SLC4A1 RHAG
13 glycolytic process GO:0006096 9.35 PKLR PGK1 HK1 GPI ALDOA
14 glucose 6-phosphate metabolic process GO:0051156 9.33 HK1 GPI G6PD
15 muscle cell cellular homeostasis GO:0046716 9.25 ALDOA
16 canonical glycolysis GO:0061621 9.02 PKLR PGK1 HK1 GPI ALDOA

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.87 PKLR PGK1 HK1 GSS GCLC EPB42
2 catalytic activity GO:0003824 9.67 PKLR HK1 GCLC ALDOA
3 magnesium ion binding GO:0000287 9.46 PKLR NT5C3A GSS GCLC
4 glucose binding GO:0005536 9.26 HK1 G6PD
5 structural constituent of cytoskeleton GO:0005200 9.26 SPTB SPTA1 EPB42 ANK1
6 ankyrin binding GO:0030506 8.8 SPTB SLC4A1 RHAG

Sources for Hemolytic Anemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....